Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN. Scheijen B, et al. Among authors: van ingen schenau d. Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15. Haematologica. 2017. PMID: 27979924 Free PMC article.
Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.
Yuniati L, van der Meer LT, Tijchon E, van Ingen Schenau D, van Emst L, Levers M, Palit SA, Rodenbach C, Poelmans G, Hoogerbrugge PM, Shan J, Kilberg MS, Scheijen B, van Leeuwen FN. Yuniati L, et al. Among authors: van emst l, van ingen schenau d, van der meer lt, van leeuwen fn. Oncotarget. 2016 Jan 19;7(3):3128-43. doi: 10.18632/oncotarget.6519. Oncotarget. 2016. PMID: 26657730 Free PMC article.
Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN, Scheijen B. Marke R, et al. Among authors: van ingen schenau d, van leeuwen fn. Leukemia. 2016 Jul;30(7):1599-603. doi: 10.1038/leu.2015.359. Epub 2015 Dec 29. Leukemia. 2016. PMID: 26713593 No abstract available.
Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.
Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Havinga J, Rouault JP, Hoogerbrugge PM, van Leeuwen FN, Scheijen B. Tijchon E, et al. Among authors: van emst l, van ingen schenau d, van leeuwen fn. Haematologica. 2016 Jul;101(7):e272-6. doi: 10.3324/haematol.2015.139675. Epub 2016 Apr 1. Haematologica. 2016. PMID: 27036158 Free PMC article. No abstract available.
In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.
van der Meer LT, Terry SY, van Ingen Schenau DS, Andree KC, Franssen GM, Roeleveld DM, Metselaar JM, Reinheckel T, Hoogerbrugge PM, Boerman OC, van Leeuwen FN. van der Meer LT, et al. Among authors: van ingen schenau ds. J Nucl Med. 2017 Feb;58(2):214-220. doi: 10.2967/jnumed.116.177741. Epub 2016 Aug 4. J Nucl Med. 2017. PMID: 27493268 Free article.
Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Gerritsen M, van der Meer LT, Williams O, Hoogerbrugge PM, Scheijen B, van Leeuwen FN. Tijchon E, et al. Among authors: van ingen schenau d. Exp Hematol. 2018 Apr;60:57-62.e3. doi: 10.1016/j.exphem.2018.01.006. Epub 2018 Feb 8. Exp Hematol. 2018. PMID: 29408281 Free article.
The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.
Vrenken KS, Vervoort BMT, van Ingen Schenau DS, Derks YHW, van Emst L, Grytsenko PG, Middelbeek JAJ, van Leeuwen FN. Vrenken KS, et al. Among authors: van ingen schenau ds. Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165644. doi: 10.1016/j.bbadis.2019.165644. Epub 2019 Dec 17. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 31862304 Free article.
BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
Butler M, van Ingen Schenau DS, Yu J, Jenni S, Dobay MP, Hagelaar R, Vervoort BMT, Tee TM, Hoff FW, Meijerink JP, Kornblau SM, Bornhauser B, Bourquin JP, Kuiper RP, van der Meer LT, van Leeuwen FN. Butler M, et al. Among authors: van ingen schenau ds. Blood. 2021 Dec 9;138(23):2383-2395. doi: 10.1182/blood.2021011787. Blood. 2021. PMID: 34280258 Free PMC article. Clinical Trial.
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K, Macho-Maschler S, Van Ingen Schenau DS, Butler M, Lassnig C, Valcanover D, Poelzl A, Meissl K, Maurer B, Brandstoetter T, Vogl C, Koren A, Kubicek S, Orlova A, Moriggl R, Strobl B, Sexl V, Van Leeuwen FN, Kuiper RP, Mueller M. Woess K, et al. Among authors: van ingen schenau ds. Haematologica. 2023 Apr 1;108(4):993-1005. doi: 10.3324/haematol.2021.279848. Haematologica. 2023. PMID: 35021603 Free PMC article.
22 results